<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072082</url>
  </required_header>
  <id_info>
    <org_study_id>DLT-2016</org_study_id>
    <nct_id>NCT03072082</nct_id>
  </id_info>
  <brief_title>Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization</brief_title>
  <official_title>Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Danlou Tablet is effective in the treatment
      of coronary artery disease not amenable to revascularization on the basis of western medicine
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The western medicine treatment for CAD not amenable to revascularization is limited. Danlou
      Tablet, a kind of Chinese patent medicine has been used for treating coronary artery disease
      in clinical practice in China for many years.

      Danlou Tablet is applicable to &quot;phlegm-stasis syndrome&quot; in Traditional Chinese Medicine.
      According to recent studies, Danlou Tablet can reduce blood lipid level and myocardial
      necrosis area ,promote infarct healing in rats.And it can improve clinical symptoms of
      patients with CAD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Six months after randomisation</time_frame>
    <description>Death caused by cardiovascular disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction percentage (EF%)</measure>
    <time_frame>At baseline (before randomisation), and six months after randomisation</time_frame>
    <description>One of Echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E/A ratio</measure>
    <time_frame>At baseline (before randomisation), and six months after randomisation</time_frame>
    <description>One of Echocardiographic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>At baseline (before randomisation), and six months after randomisation.</time_frame>
    <description>CRP in Î¼g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>At baseline (before randomisation), and six months after randomisation.</time_frame>
    <description>BNP in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission rates</measure>
    <time_frame>At baseline (before randomisation), and six months after randomisation.</time_frame>
    <description>Hospital readmission rates due to coronary artery disease during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Coronary Artery Disease(CAD)</condition>
  <arm_group>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months &amp; conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months &amp; conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danlou Tablet</intervention_name>
    <description>Conventional western medicine &amp; Danlou Tablet</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DanLou Tablet placebo</intervention_name>
    <description>Conventional western medicine &amp; placebo (for Danlou Tablet)</description>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets</intervention_name>
    <description>100 mg tablet, one tablet daily.</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet</intervention_name>
    <description>One tablet daily. (for patients who can't use aspirin)</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin calcium</intervention_name>
    <description>10 mg tablet, two tablets each night.</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate Tab 20 MG</intervention_name>
    <description>One tablet two times daily.</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <other_name>Xinkang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Tartrate Tab 25 MG</intervention_name>
    <description>12.5 mg or 25 mg two times daily.</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <other_name>Metoprolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine Dihydrochloride Tablets</intervention_name>
    <description>20 mg tablet, one tablet three times daily.</description>
    <arm_group_label>Danlou Tablet</arm_group_label>
    <arm_group_label>Danlou Tablet placebo</arm_group_label>
    <other_name>Vasorel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are aged between 45 and 75 years, diagnosed with sever CAD through
             coronary arteriography which shows that the left main coronary artery and three-vessel
             have sever diffuse stenosis, calcification or vascular ectasia, be in accordance with
             Traditional Chinese Medicine syndrome of &quot;Qi deficiency and blood stasis syndrome&quot; or
             &quot;phlegm and stasis mu-tual obstruction syndrome&quot;.

        Exclusion Criteria:

          -  Patients with severe valvular disease, congenital cardiomyopathy decompensation

          -  Patients with CAD complicated with severe multiple organ disease such as severe heart
             failure, severe lung, liver or renal dysfunction, peptic ulcer in active stage, or
             intracranial hemorrhage

          -  Patients that use high-dose steroids due to connective tissue disease

          -  Patients with serious infections

          -  Patients with malignant tumor

          -  Patients with hematopoietic diseases

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, MD</last_name>
    <phone>+86 13051458913</phone>
    <email>13051458913@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Panpan Tian</last_name>
    <phone>+86 15652388175</phone>
    <email>15652388175@163.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Zhao D. [Why dentists need to learn the epidemiological status and prevention strategy of coronary heart disease in China]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2016 Jul;51(7):385-6. doi: 10.3760/cma.j.issn.1002-0098.2016.07.001. Chinese.</citation>
    <PMID>27480425</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu H, Luo XP, Wang LJ. [Evaluation on clinical effect of long-term shexiang baoxin pill administration for treatment of coronary heart disease]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 May;30(5):474-7. Chinese.</citation>
    <PMID>20681275</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou Z, Shen W, Yu L, Xu C, Wu Q. A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review. J Ethnopharmacol. 2016 Dec 24;194:1130-1139. doi: 10.1016/j.jep.2016.11.024. Epub 2016 Nov 12.</citation>
    <PMID>27847338</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry TD. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010 May 1;75(6):886-91. doi: 10.1002/ccd.22431.</citation>
    <PMID>20432394</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta S, Pressman GS, Morris DL, Figueredo VM. Distribution of left ventricular ejection fraction in angina patients with severe coronary artery disease not amenable to revascularization. Coron Artery Dis. 2010 Aug;21(5):278-80. doi: 10.1097/MCA.0b013e32833bdf53.</citation>
    <PMID>20531008</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan AW, Tetzlaff JM, GÃ¸tzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, HrÃ³bjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.</citation>
    <PMID>23303884</PMID>
  </results_reference>
  <results_reference>
    <citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672-7. doi: 10.1016/j.ijsu.2011.09.004. Epub 2011 Oct 13.</citation>
    <PMID>22019563</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang L, Mao S, Qi JY, Ren Y, Guo XF, Chen KJ, Zhang MZ. Effect of Danlou Tablet () on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial. Chin J Integr Med. 2015 Sep;21(9):662-6. doi: 10.1007/s11655-015-2284-1. Epub 2015 Jul 4.</citation>
    <PMID>26142341</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang SH, Wang J, Li J. [Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Aug;32(8):1051-5. Chinese.</citation>
    <PMID>23173251</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Cai HW, Miao J, Xu XM, Mao W. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jun;36(6):703-8. Chinese.</citation>
    <PMID>27491230</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun Li</investigator_full_name>
    <investigator_title>Director of Cardiology</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>revascularization</keyword>
  <keyword>Danlou Tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

